DrugPatentWatch Database Preview
Drugs in Development Information for Lucitanib
» See Plans and Pricing
What is the drug development status for Lucitanib?
Lucitanib is an investigational drug.
There have been 9 clinical trials for Lucitanib.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 14th 2019.
The most common disease conditions in clinical trials are Small Cell Lung Carcinoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Clovis Oncology, Inc., Servier, and Bristol-Myers Squibb.
There are fifteen US patents protecting this investigational drug and one hundred and twenty-nine international patents.
Summary for Lucitanib
| US Patents | 15 |
| International Patents | 129 |
| US Patent Applications | 23 |
| WIPO Patent Applications | 162 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2019-11-14) |
| Vendors | 39 |
Recent Clinical Trials for Lucitanib
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and Immunotherapy | Bristol-Myers Squibb | Phase 1/Phase 2 |
| This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients | ShangHai HaiHe Pharmaceutical | Phase 2/Phase 3 |
| A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | Bristol-Myers Squibb | Phase 1/Phase 2 |
Clinical Trial Summary for Lucitanib
Top disease conditions for Lucitanib
Top clinical trial sponsors for Lucitanib
US Patents for Lucitanib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Lucitanib | Start Trial | Human anti-VEGFR-2/KDR antibodies | KADMON CORPORATION, LLC (New York, NY) | Start Trial |
| Lucitanib | Start Trial | Rho kinase inhibitors | KADMON CORPORATION, LLC (New York, NY) | Start Trial |
| Lucitanib | Start Trial | Rho kinase inhibitors | Kadmon Corporation, LLC (New York, NY) | Start Trial |
| Lucitanib | Start Trial | Human anti-VEGFR-2/KDR antibodies | Kadmon Corporation, LLC (New York, NY) | Start Trial |
| Lucitanib | Start Trial | Self-emulsifying formulations of DIM-related indoles | BioResponse, L.L.C. (Boulder, CO) | Start Trial |
| Lucitanib | Start Trial | Deuterated triazolopyridazine as a kinase modulator | Janssen Pharmaceutica NV (Beerse, BE) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Lucitanib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Lucitanib | Canada | CA2926386 | 2032-10-05 | Start Trial |
| Lucitanib | China | CN105007939 | 2032-10-05 | Start Trial |
| Lucitanib | China | CN109160950 | 2032-10-05 | Start Trial |
| Lucitanib | Eurasian Patent Organization | EA032679 | 2032-10-05 | Start Trial |
| Lucitanib | Eurasian Patent Organization | EA201500363 | 2032-10-05 | Start Trial |
| Lucitanib | Eurasian Patent Organization | EA201990403 | 2032-10-05 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
